Axsome Therapeutics ($AXSM) Stock Hub 2026: SUMMIT Phase 3 Starts as AUVELITY’s Alzheimer’s Launch Enters Its First Full Quarter

01 The central question: can commercial growth finally outrun the cost of selling?

Axsome has already crossed the threshold that separates development-stage biotechnology from commercial biotechnology. It does not need a future FDA approval to prove that doctors will prescribe one of its drugs. AUVELITY alone produced $180.3 million of net sales in the second quarter of 2026, SUNOSI produced $33.8 million of product sales and SYMBRAVO produced another $2.3 million.

The unresolved question is economic rather than scientific. Total second-quarter revenue was $218.375 million. Cost of revenue was only $13.564 million, which implies a quarterly gross margin of approximately 93.8% before amortisation and depreciation. Yet operating expenses reached $268.021 million because the company spent $46.227 million on research and development and $208.137 million on selling, general and administrative expenses.

That structure creates enormous potential operating leverage if revenue continues rising without a comparable increase in the commercial cost base. It also creates a clear downside if growth slows before that crossover occurs.

02 What Axsome actually does today

Axsome Therapeutics, Inc. is headquartered in New York and develops and commercialises medicines for central nervous system disorders. Its current operating business rests on three marketed medicines and an increasingly broad late-stage pipeline.

The revenue concentration remains important. AUVELITY represented approximately 82.6% of total Q2 revenue. SUNOSI represented about 16.4% when product, royalty and milestone revenue are combined. SYMBRAVO remained roughly one per cent.

That means the broad pipeline should not hide the current economic reality: for the next several quarters, AXSM remains primarily an AUVELITY commercial execution story.

03 The three marketed medicines

Revenue mix

Product concentration is the clearest current operating risk. The pipeline may eventually diversify the company, but today neither SUNOSI nor SYMBRAVO is large enough to offset a meaningful AUVELITY disappointment.

04 AUVELITY: the Alzheimer’s agitation launch becomes measurable

AUVELITY was originally approved in August 2022 for major depressive disorder in adults and launched in October 2022. On April 30, 2026 the FDA approved it for agitation associated with dementia due to Alzheimer’s disease following Priority Review and previous Breakthrough Therapy designation.

Commercial launch for the new indication began in June 2026. That timing is important because the second quarter contains only a partial commercial period for Alzheimer’s agitation while much of the launch infrastructure was already in the expense base.

Axsome reported approximately 266,000 AUVELITY prescriptions during Q2 and described the figure as 34% year-over-year and 12% sequential growth. Because the company reports rounded prescription counts, the rounded quarterly totals do not reproduce every stated percentage exactly.

The most informative early launch datapoint was new-to-brand prescriptions among patients aged 65 and older. Axsome said this measure increased 126% during the first eight weeks following launch compared with the equivalent period in the preceding quarter.

Payer access was approximately 89% of covered lives at Q2, including roughly 82% of commercial lives and approximately 100% of government lives.

Coverage is not the same as utilisation. Prior authorisation, formulary positioning, co-pay support, physician awareness, patient tolerability and caregiver acceptance still determine whether access becomes a prescription and whether a prescription becomes net revenue.

05 The commercial engine: revenue, prescriptions and selling cost

The series shows real growth but not a perfectly straight line. The first quarter of 2026 was the only sequential decline in the six-quarter sequence before revenue reached a new high in Q2.

Year over year, Q2 revenue increased by approximately $68.3 million. SG&A increased from $130.3 million to $208.1 million, an increase of roughly $77.9 million.

The company attributes the higher commercial cost to AUVELITY commercial activities, including launch preparation and sales-force expansion around Alzheimer’s agitation, a national direct-to-consumer advertising campaign, SYMBRAVO commercial activity and higher personnel costs.

06 SUNOSI and SYMBRAVO: smaller today, strategically important tomorrow

SUNOSI

SUNOSI generated $33.820 million of second-quarter product sales. Axsome also recognised approximately $1.474 million of SUNOSI royalty revenue and $546 thousand of milestone revenue, bringing the product’s total contribution to approximately $35.8 million.

Approximately 61,000 U.S. prescriptions were written during Q2, up 14% year over year and 8% sequentially according to the company. Payer coverage was approximately 82% of covered lives.

SUNOSI is strategically more important than its current revenue contribution alone suggests because solriamfetol is being developed across multiple additional conditions. Successful expansion could allow Axsome to leverage an existing molecule and commercial infrastructure rather than building every franchise from zero.

SYMBRAVO

SYMBRAVO remains the smallest commercial franchise. Approximately 23,500 prescriptions were written in Q2, which Axsome described as a 30% sequential increase, yet net product sales were only $2.253 million versus approximately $4.073 million in the first quarter.

The filing does not provide enough product-specific gross-to-net information to reconcile that divergence. Channel inventory, rebates, co-pay assistance and estimate adjustments can affect young product launches, but assigning the difference to any one mechanism without disclosure would be speculation.

07 Pipeline map: filed, active Phase 3 and earlier optionality

08 SUMMIT: AXS-05 enters Phase 3 in smoking cessation

On August 31, Axsome announced the first patient had been dosed in SUMMIT. The trial evaluates AXS-05 in adults seeking smoking cessation.

The study is described as Phase 3, randomized, double-blind, active- and placebo-controlled and multicenter. Participants are randomized 1:1:1 to AXS-05, bupropion or placebo and treated for approximately twelve weeks.

The primary endpoint is smoking abstinence at the end of the treatment period.

The active bupropion comparator is analytically important because bupropion itself is an established smoking-cessation therapy. AXS-05 therefore has to demonstrate value in a setting where one component already has known therapeutic activity rather than merely outperforming placebo.

09 Solriamfetol expansion: four development paths beyond current SUNOSI use

ENGAGE — binge eating disorder

ENGAGE is the most immediate clinical catalyst in the portfolio. Axsome guides Phase 3 topline results to the fourth quarter of 2026.

A positive outcome would not constitute an approval, but it could support another regulatory pathway for a molecule already marketed in a different indication.

SUSTAIN — shift work disorder

SUSTAIN is evaluating solriamfetol for excessive sleepiness associated with shift work disorder. Axsome continues to guide topline results to 2027.

CLARITY — MDD with excessive daytime sleepiness

The CLARITY Phase 3 programme examines solriamfetol in patients with major depressive disorder who also experience excessive daytime sleepiness symptoms.

FOCUS-2 and FOCUS-3 — paediatric ADHD

Axsome initiated FOCUS-3 in adolescents in June and FOCUS-2 in children in July 2026. Both are randomized Phase 3 programmes evaluating solriamfetol in ADHD.

FOCUS-2 is designed to enrol approximately 468 children aged 6 to under 12, randomized among two solriamfetol doses and placebo for six weeks, with change in ADHD-RS-5 total score as the primary endpoint.

10 AXS-12: the nearest FDA binary

AXS-12 is reboxetine, being developed for cataplexy associated with narcolepsy. The FDA accepted Axsome’s NDA for filing in July 2026 and assigned a target action date of May 1, 2027.

Axsome said the FDA does not currently plan to hold an advisory committee meeting. That can reduce one procedural source of uncertainty, but it should not be interpreted as an approval signal.

AXS-12 has FDA Orphan Drug designation for narcolepsy.

The development package includes completed placebo-controlled efficacy studies and longer-term safety work. As with any NDA review, the FDA can approve, delay action, request additional information, issue a Complete Response Letter or approve a narrower label than the sponsor seeks.

11 AXS-14, AXS-17 and AXS-20

AXS-14 — fibromyalgia

AXS-14 is esreboxetine. Axsome initiated FORWARD, a Phase 3 randomized-withdrawal programme in fibromyalgia, in January 2026.

Earlier clinical studies provide evidence supporting the programme, but FORWARD is the active programme relevant to the current regulatory path.

AXS-17 — epilepsy

AXS-17 is an oral GABA_A receptor alpha-2,3 subtype-selective positive allosteric modulator. Axsome describes Phase 2 trial-enabling activities as underway.

AXS-20 — balipodect

Axsome acquired global rights to balipodect from Takeda in the first quarter of 2026 for $10.4 million including transaction costs. Because the transaction was treated as an asset acquisition, the purchase cost was expensed through research and development.

Takeda is eligible for up to $260 million of development, regulatory and sales-based milestones plus a mid-single-digit royalty on potential global net sales.

Axsome is conducting Phase 3-enabling work in schizophrenia and also plans to evaluate the compound in Tourette syndrome.

12 Financial baseline: Q2 2026 and first half

The revenue growth is genuine. Second-quarter total revenue rose 45.5% from $150.042 million a year earlier.

The operating leverage is not yet visible in GAAP earnings because commercial spending expanded even faster in absolute dollars.

Stock-based compensation was $27.1 million in Q2. It is non-cash in the period in which it is expensed, but it is not economically irrelevant because equity compensation contributes to the fully diluted ownership structure.

13 Cash flow: better than last year, still not self-funding

The improvement in operating cash flow is meaningful. Axsome used $53.7 million of operating cash during the first half compared with $75.8 million in the comparable 2025 period, an improvement of approximately $22.1 million.

Management attributed the improvement primarily to higher product revenue, partly offset by increased commercial and clinical activity.

But the small $3.1 million decline in headline cash should not be confused with near-breakeven operations. Financing activities supplied $51.1 million of cash during the half.

Those financing inflows included approximately $19.8 million of gross common-stock proceeds under the ATM programme and $51.9 million of proceeds from option exercises and the employee stock purchase plan, partly offset by other financing uses.

14 Debt and liquidity: what the Blackstone facility actually looks like

Axsome entered the Blackstone financing arrangement in May 2025. The structure included a $120 million first-lien senior secured term loan funded at closing, two potential additional $90 million term-loan tranches and a super-senior revolving facility.

The first optional $90 million term-loan commitment expired unused on May 31, 2026.

The second $90 million optional term-loan commitment remains available until May 31, 2027.

On June 26, 2026, Axsome increased the revolving commitments by $20 million, from $70 million to $90 million.

The term loan bears interest at Term SOFR plus 4.75%. The effective term-loan rate was 9.58% during the first half. The revolver bears SOFR plus 4.0%, and the weighted-average rate at June 30 was 7.73%.

The July repayment changes the correct presentation of the balance sheet. The $70 million shown as short-term borrowings on June 30 was real, but it was not still outstanding after the subsequent repayment disclosed in the 10-Q.

15 Dilution: modest headline growth, but the ATM remains active

Shares outstanding were 50,882,766 at December 31, 2025 and 52,299,889 at June 30, 2026, an increase of approximately 2.8%.

The Form 10-Q cover shows 52,380,818 common shares outstanding as of August 3, 2026.

ATM activity

This is an important correction to the prior version of the hub. The Q1 filing only showed the first $6.3 million of ATM activity. The Q2 filing confirms that Axsome continued using the programme during the second quarter.

The magnitude remains modest relative to the company’s approximately $10 billion equity value, but an active ATM is still an active source of dilution and should remain on the monitoring list.

The Form 10-Q also identifies millions of potential common-stock equivalents associated with options, restricted stock units, warrants and other awards. Fully diluted ownership can therefore differ materially from the basic share count.

16 Management, governance and the Antecip related-party royalty

Axsome is led by founder Herriot Tabuteau, M.D., who serves as President, Chief Executive Officer and Chairman.

Other senior executives include Chief Financial Officer Nick Pizzie, Chief Operating Officer Mark Jacobson, General Counsel Hunter Murdock and Chief Commercial Officer Ari Maizel.

The combination of chief executive and chairman roles concentrates authority. The board uses a lead independent director structure as a counterbalance.

The Antecip royalty

Axsome licenses intellectual property related to AXS-05 from Antecip Bioventures II LLC, an entity owned by Dr. Tabuteau.

The agreement requires a royalty equal to 3.0% of AUVELITY net sales, subject to specified potential adjustments.

The Q2 Form 10-Q records $5.3 million of royalty expense due to Antecip during the second quarter and $9.9 million during the first half of 2026.

The corresponding first-half 2025 amount was $6.5 million.

Customer concentration

For the first six months of 2026, the company’s three largest customers represented approximately 38%, 27% and 24% of gross product sales — approximately 89% combined.

High wholesaler concentration is common in U.S. pharmaceuticals, but the number helps explain why accounts receivable and distributor relationships deserve attention alongside prescription demand.

17 Patent protection and litigation

Intellectual-property duration is a major part of the long-term valuation because Axsome is investing heavily in commercial infrastructure that only creates durable value if the underlying products retain meaningful exclusivity.

AUVELITY

The company’s annual filing describes an extensive U.S. patent estate around AXS-05/AUVELITY extending well into the next decade.

Axsome previously reached a settlement with Teva concerning AUVELITY that provides for potential generic entry no earlier than the settlement dates specified in the company’s filings, subject to the detailed conditions in the agreement and applicable exclusivity.

SUNOSI

Axsome announced on June 3, 2026 that all U.S. patent litigation relating to SUNOSI had been resolved.

SYMBRAVO

The company remains involved in Paragraph IV patent litigation relating to SYMBRAVO. Litigation outcomes are uncertain and should not be treated as either guaranteed protection or guaranteed generic entry.

18 Market data: what the current valuation implies

AXSM closed at $199.01 on August 28, 2026. That close is used below only to date the valuation figure.

Using the 52,380,818 shares outstanding reported on the August 3 Form 10-Q cover, that price implies an equity value of approximately $10.42 billion. This is a Merlintrader calculation rather than a company-reported market-cap figure.

A share price does not change the clinical or regulatory facts, but it does change the valuation investors are paying for the same commercial franchise and development pipeline.

The company remains valued as a high-growth commercial biotechnology business. That valuation requires investors to assume that AUVELITY’s expanded label, SUNOSI lifecycle development and the pipeline can eventually generate enough earnings and cash flow to justify a multi-billion-dollar enterprise before financing claims are deducted.

19 Retail sentiment: bullish posts, bearish normalized signal

The Stocktwits snapshot on August 31 produced an unusual split between legacy tagged-message percentages and the platform’s normalized current sentiment.

Discussion on August 31 quickly incorporated the SUMMIT initiation. Positive posts focused on the expanding pipeline and the idea that commercial investment could precede eventual profitability.

Negative or cautious discussion centred more on recent share-price weakness and the continued expense burden.

Neither side should be treated as primary research. Sentiment measures attention and positioning, not clinical probability or fundamental value.

20 Scenario framework for the next 12–18 months

Most outcomes will lie between these extremes. The purpose of the framework is not to assign probabilities but to identify the evidence that would move the investment case from one path toward the other.

21 Red flags and thesis-breakers

• AUVELITY growth fails to accelerate despite a full quarter of the Alzheimer’s agitation indication.
• SG&A increases substantially more than “marginally” through the remainder of 2026.
• Operating cash use worsens after the first-half improvement.
• ATM issuance accelerates materially relative to the $19.8 million of gross first-half proceeds.
• The optional $90 million Blackstone term tranche is drawn primarily to fund recurring losses rather than a clearly identifiable growth investment.
• SYMBRAVO net revenue remains disconnected from prescription growth.
• ENGAGE slips beyond Q4 2026 or produces an unsuccessful result.
• SUMMIT enrolment or execution encounters a material delay.
• AXS-12 receives a review extension, unexpected advisory committee or adverse FDA development.
• Payer access or gross-to-net economics deteriorate for AUVELITY.
• Accounts receivable or distributor concentration grows materially without corresponding revenue conversion.
• Patent litigation materially weakens expected exclusivity.

22 Evergreen monitoring checklist

23 Merlintrader bottom line

Axsome entered the final part of 2026 with a stronger operating business and a broader late-stage pipeline than it had at the start of the year.

AUVELITY now has two approved indications. Q2 total revenue reached $218.4 million. The Alzheimer’s agitation indication was commercially active for only part of the quarter, making Q3 the first genuinely useful full-period read on the launch.

The pipeline also moved forward. AXS-12 is under FDA review with a May 1, 2027 PDUFA target date. ENGAGE remains guided to deliver Phase 3 data in Q4 2026. On August 31, SUMMIT formally began dosing patients in the smoking-cessation Phase 3 programme.

The problem is equally visible. Q2 SG&A was $208.1 million, almost equal to quarterly revenue. Management expects SG&A to increase marginally through year-end rather than fall immediately. Axsome used $53.7 million of operating cash in the first half and offset much of that with financing cash flows.

The balance sheet is more nuanced than the old version of this hub suggested. The June 30 revolver balance was not permanent: the $70 million was repaid in July. At the same time, the company increased revolver capacity to $90 million, kept another $90 million optional term-loan tranche available until May 2027 and continued selling shares through its ATM.

The core question is therefore unusually clean for a biotechnology company: does AUVELITY’s expanded commercial opportunity grow faster than the infrastructure Axsome has built to capture it?

If the answer begins turning positive over the next several quarters, the high gross margin gives Axsome room for rapid operating leverage. If it does not, the same pipeline breadth that supports the long-term opportunity will continue consuming capital.

The next evidence is not a distant scientific theory. It is the third-quarter income statement, the third-quarter cash-flow statement, the ENGAGE Phase 3 result in Q4 and then the AXS-12 FDA review.

24 Related Merlintrader research

Readers following commercial-stage biotechnology, upcoming FDA decisions and late-stage clinical catalysts can also use the Merlintrader biotech ranking and catalyst calendar.

Top Ten Biotech Stocks Right Now

Merlintrader Biotech / Tech Catalyst Calendar